The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | The role of NT219 in enhancing anti-PD-1 efficacy
Ricardo De Azevedo, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses an assessment of NT219, a novel dual inhibitor of insulin receptor substrates 1 and 2 (IRS) and STAT3, in combination with anti-PD-1 and anti-CTLA-4 ICB, to overcome immune resistance. A significant synergistic effect of NT219 combined with anti-PD-1 therapy, supported by a mechanism of PDL-1 induction making immune checkpoint inhibitor (ICI) resistant tumors amenable to ICI treatment, was found. The findings demonstrated that NT219 has the potential to reverse ICI resistance in both human PDX and murine syngeneic tumor model systems. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
